X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (71) 71
respiratory system (54) 54
male (50) 50
middle aged (46) 46
female (44) 44
adult (38) 38
copd (35) 35
aged (34) 34
pulmonary disease, chronic obstructive - drug therapy (34) 34
obstructive pulmonary-disease (33) 33
asthma (32) 32
index medicus (32) 32
double-blind method (27) 27
tiotropium (26) 26
treatment outcome (24) 24
lung diseases, obstructive (21) 21
chronic obstructive pulmonary disease (20) 20
administration, inhalation (19) 19
bronchodilator agents - administration & dosage (17) 17
forced expiratory volume (17) 17
bronchodilator agents - therapeutic use (16) 16
cross-over studies (16) 16
efficacy (15) 15
research (15) 15
respiratory tract diseases (15) 15
indacaterol (14) 14
inflammation (14) 14
pharmacology & pharmacy (14) 14
pulmonary and respiratory medicine (14) 14
pulmonary disease, chronic obstructive - physiopathology (14) 14
drug therapy (13) 13
time factors (13) 13
tiotropium bromide (13) 13
allergy (12) 12
asthma - drug therapy (12) 12
drug administration schedule (12) 12
exacerbations (12) 12
salmeterol (12) 12
severity of illness index (12) 12
induced sputum (11) 11
pulmonary disease, chronic obstructive - diagnosis (10) 10
scopolamine derivatives - therapeutic use (10) 10
airway inflammation (9) 9
analysis (9) 9
bronchodilator agents - adverse effects (9) 9
immunology (9) 9
medicine, research & experimental (9) 9
sputum - cytology (9) 9
adolescent (8) 8
cardiac & cardiovascular systems (8) 8
diseases of the respiratory system (8) 8
double-blind (8) 8
drug therapy, combination (8) 8
medicine, general & internal (8) 8
original research (8) 8
therapy (8) 8
adrenergic beta-agonists - therapeutic use (7) 7
aged, 80 and over (7) 7
asthma - immunology (7) 7
care and treatment (7) 7
deficiency (7) 7
exercise (7) 7
glutathione (7) 7
lung - physiopathology (7) 7
lung hyperinflation (7) 7
muscarinic antagonists - administration & dosage (7) 7
neutrophils (7) 7
pharmaceutical industry (7) 7
pharmacology (7) 7
pulmonary/respiratory (7) 7
respiratory agents (7) 7
sputum - chemistry (7) 7
studies (7) 7
abridged index medicus (6) 6
adrenergic beta-2 receptor agonists - therapeutic use (6) 6
asthma - diagnosis (6) 6
asthma - metabolism (6) 6
asthma - physiopathology (6) 6
clinical trials (6) 6
cytokines (6) 6
dosage and administration (6) 6
dyspnea (6) 6
glycopyrrolate - administration & dosage (6) 6
indans - therapeutic use (6) 6
lower respiratory-tract (6) 6
lung - drug effects (6) 6
quality-of-life (6) 6
quinolones - therapeutic use (6) 6
safety (6) 6
salmeterol xinafoate (6) 6
sputum (6) 6
trial (6) 6
albuterol - analogs & derivatives (5) 5
albuterol - therapeutic use (5) 5
allergens (5) 5
cell (5) 5
disease (5) 5
dose-response relationship, drug (5) 5
drug combinations (5) 5
exercise performance (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of COPD, ISSN 1176-9106, 2012, Volume 7, pp. 503 - 513
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2011, Volume 364, Issue 12, pp. 1093 - 1103
Journal Article
Allergy, ISSN 0105-4538, 03/2005, Volume 60, Issue 3, pp. 309 - 316
Background: Patients with severe persistent asthma who are inadequately controlled despite Global Initiative for Asthma (GINA) 2002 step 4 therapy are a... 
omalizumab | Global Initiative for Asthma 2002 step 4 therapy | severe persistent asthma | exacerbations | anti-immunoglobulin E | anti‐immunoglobulin E | Omalizumab | Anti-immunoglobulin E | Exacerbations | Global initiative for asthma 2002 step 4 therapy | Severe persistent asthma | POPULATION | MULTICENTER | RISK-FACTORS | EFFICACY | SEVERE ALLERGIC-ASTHMA | IMMUNOLOGY | ANTIIMMUNOGLOBULIN-E ANTIBODY | LONG-TERM CONTROL | ALLERGY | TOLERABILITY | QUALITY-OF-LIFE | ANTI-IGE ANTIBODY | Anti-Asthmatic Agents - adverse effects | Anti-Asthmatic Agents - therapeutic use | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Receptors, Adrenergic, beta-2 - drug effects | Adrenal Cortex Hormones - therapeutic use | Dose-Response Relationship, Drug | Forced Expiratory Volume | Antibodies, Monoclonal, Humanized | Adult | Female | Adrenergic beta-Agonists - therapeutic use | Drug Therapy, Combination | Severity of Illness Index | Asthma - physiopathology | Double-Blind Method | Administration, Inhalation | Treatment Outcome | Asthma - drug therapy | Retreatment | Adolescent | Quality of Life | Aged | Patient Admission - statistics & numerical data | Antibodies, Anti-Idiotypic | Adrenal Cortex Hormones - administration & dosage | Respiratory therapy | Initiatives | Medical treatment | Asthma
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 21, pp. 1987 - 1995
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2014, Volume 108, Issue 4, pp. 584 - 592
Summary Introduction QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2 -agonist indacaterol... 
Pulmonary/Respiratory | QVA149 | Tiotropium | Chronic obstructive pulmonary disease | Exercise | Hyperinflation | PLACEBO | CARDIAC & CARDIOVASCULAR SYSTEMS | DAILY NVA237 | EFFICACY | SAFETY | BRONCHODILATION | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | TWICE-DAILY SALMETEROL | ONCE-DAILY INDACATEROL | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Exercise Tolerance - drug effects | Indans - therapeutic use | Lung Volume Measurements | Vital Capacity - drug effects | Quinolones - adverse effects | Spirometry - methods | Quinolones - therapeutic use | Adult | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Scopolamine Derivatives - therapeutic use | Tiotropium Bromide | Glycopyrrolate - adverse effects | Double-Blind Method | Drug Administration Schedule | Glycopyrrolate - therapeutic use | Treatment Outcome | Glycopyrrolate - analogs & derivatives | Cross-Over Studies | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Aged | Pulmonary Disease, Chronic Obstructive - drug therapy | Medicine, Experimental | Medical research | Lung diseases, Obstructive | Confidence intervals | Drug therapy
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2013, Volume 131, Issue 3, pp. 866 - 874
Journal Article
International Journal of COPD, ISSN 1176-9106, 11/2016, Volume 11, Issue 1, pp. 2877 - 2884
Background: Treating symptoms and preventing exacerbations are key components of chronic obstructive pulmonary disease (COPD) long-term management. Recently, a... 
Winter | Sputum | Myrtol | Exacerbations | Phytotherapy | Chronic bronchitis | COPD | MULTICENTER | ESSENTIAL OILS | EFFICACY | phytotherapy | PREVENTION | winter | sputum | OBSTRUCTIVE PULMONARY-DISEASE | IN-VITRO | REDUCTION | myrtol | RESPIRATORY SYSTEM | exacerbations | TOLERABILITY | TIOTROPIUM | chronic bronchitis | MUCUS HYPERSECRETION | Cough - physiopathology | Cough - drug therapy | Humans | Middle Aged | Male | Bronchitis, Chronic - diagnosis | Pulmonary Disease, Chronic Obstructive - physiopathology | Monoterpenes - adverse effects | Sputum - drug effects | Time Factors | Respiratory System Agents - administration & dosage | Aged, 80 and over | Adult | Female | Monoterpenes - administration & dosage | Respiratory System Agents - adverse effects | Seasons | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Lung - physiopathology | Pulmonary Disease, Chronic Obstructive - complications | Bronchitis, Chronic - physiopathology | Disease Progression | Bronchitis, Chronic - drug therapy | Cough - etiology | Bronchitis, Chronic - complications | Lung - drug effects | Aged | Health Status | Anti-Bacterial Agents - administration & dosage | Drug Combinations | Germany | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Care and treatment | Usage | Development and progression | Bronchitis | Essences and essential oils | Health aspects | therapy
Journal Article
Pulmonary Pharmacology & Therapeutics, ISSN 1094-5539, 2015, Volume 32, pp. 53 - 59
Journal Article